Signaturefd LLC Increases Stock Position in Axon Enterprise, Inc (NASDAQ:AXON)

Signaturefd LLC increased its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 10.4% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 838 shares of the biotechnology company’s stock after buying an additional 79 shares during the quarter. Signaturefd LLC’s holdings in Axon Enterprise were worth $441,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Florida Financial Advisors LLC bought a new stake in Axon Enterprise during the first quarter valued at approximately $504,000. Prudent Man Advisors LLC grew its position in shares of Axon Enterprise by 1.6% in the 1st quarter. Prudent Man Advisors LLC now owns 1,298 shares of the biotechnology company’s stock worth $683,000 after buying an additional 20 shares during the period. CWM LLC grew its position in shares of Axon Enterprise by 3.2% in the 1st quarter. CWM LLC now owns 4,713 shares of the biotechnology company’s stock worth $2,479,000 after buying an additional 147 shares during the period. Arizona State Retirement System grew its position in Axon Enterprise by 0.5% during the 1st quarter. Arizona State Retirement System now owns 20,927 shares of the biotechnology company’s stock valued at $11,007,000 after purchasing an additional 107 shares during the last quarter. Finally, Realta Investment Advisors lifted its stake in Axon Enterprise by 27.6% during the 1st quarter. Realta Investment Advisors now owns 2,265 shares of the biotechnology company’s stock valued at $1,191,000 after acquiring an additional 490 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $745.86 on Friday. The business has a 50 day simple moving average of $762.11 and a 200 day simple moving average of $644.50. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. The firm has a market capitalization of $58.07 billion, a price-to-earnings ratio of 180.16, a price-to-earnings-growth ratio of 85.50 and a beta of 1.29. Axon Enterprise, Inc has a 12-month low of $279.02 and a 12-month high of $830.21.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same quarter in the prior year, the company earned $1.15 earnings per share. The company’s revenue for the quarter was up 31.3% on a year-over-year basis. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on AXON shares. JPMorgan Chase & Co. raised their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research note on Thursday. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. Wolfe Research started coverage on Axon Enterprise in a research note on Monday, July 7th. They issued an “outperform” rating on the stock. UBS Group assumed coverage on Axon Enterprise in a research note on Wednesday. They set a “neutral” rating and a $820.00 price target on the stock. Finally, Needham & Company LLC boosted their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $763.75.

Insider Buying and Selling at Axon Enterprise

In other news, CRO Cameron Brooks sold 3,000 shares of the stock in a transaction on Friday, May 30th. The stock was sold at an average price of $740.76, for a total value of $2,222,280.00. Following the transaction, the executive owned 19,447 shares of the company’s stock, valued at $14,405,559.72. This represents a 13.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Joshua Isner sold 905 shares of the stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total value of $702,632.95. Following the transaction, the president owned 268,735 shares of the company’s stock, valued at approximately $208,643,166.65. This trade represents a 0.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock valued at $30,500,428 over the last quarter. Company insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.